Investments
413Portfolio Exits
91Funds
9Partners & Customers
10Service Providers
1About Flagship Pioneering
Flagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. It's institutional innovation foundry, Flagship VentureLabs, is where Flagship's team of scientific entrepreneurs systematically evolve enterprising ideas into new fields, or previously undiscovered areas of science into real-world inventions and ventures. The firm is focused on building what it describes as bioplatform companies that focus on human health and sustainability. Flagship's model is part incubator and part venture fund. Flagship aims to be the principal founders, funders, and owners of our companies, taking responsibility for their long-term success by providing them with all the resources of our ecosystem.
Expert Collections containing Flagship Pioneering
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Flagship Pioneering in 4 Expert Collections, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Synthetic Biology
382 items
Game Changers 2018
20 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing Flagship Pioneering
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Flagship Pioneering in 1 CB Insights research brief, most recently on Feb 16, 2021.
Latest Flagship Pioneering News
Nov 30, 2023
Thermo Fisher and Flagship Pioneering partner to establish platform companies The strategic partnership between Thermo Fisher Scientific and Flagship Pioneering will focus on creating platform companies to power the biotech ecosystem and accelerate the development of first-in-class therapies. Share this article In October 2023, Thermo Fisher reported a 1% decrease in revenue in Q3 FY 2023 to $10.57bn, compared to $10.68bn in the same period last year. Thermo Fisher has announced a new partnership with biotechnology company Flagship Pioneering to establish a string of platform companies. The platform companies will focus on novel tools and capabilities that support the acceleration of first-in-class therapies and biotech ecosystems. Go deeper with GlobalData The partnership builds on an already established supply relationship between Thermo Fisher and Flagship Pioneering, which supports the latter in the following areas life science tools, diagnostics, and services. Flagship Pioneering senior partner Justine Levin-Allerhand said: “Our partnership will couple Flagship’s innovative company formation process with Thermo Fisher’s deep understanding of the life sciences industry, as we collaborate to develop transformative capabilities for the ecosystem. We are pleased to expand our relationship with Thermo Fisher and together take bigger leaps in life sciences capabilities, while further empowering our industry.” Michel Lagarde, executive vice president and chief operating officer at Thermo Fisher Scientific, said: “We look forward to seeing the accelerating effect of Thermo Fisher’s deep technical expertise and extensive commercial capabilities on the future innovations Flagship and its companies will bring to market.” In October 2023, Thermo Fisher reported a 1% decrease in revenue during the third quarter (Q3) of fiscal year (FY) 2023 to $10.57bn, compared to $10.68bn in the same period last year. In addition, their organic revenue was 3% lower and core organic revenue growth was 1%. How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network. I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the privacy policy Submit and download In the same month, Thermo Fisher set out to acquire Swedish proteomics company Olink for $3.1bn. It also acquired CorEvitas , a data intelligence company for $912.5m in cash in August 2023 after a drop in Q2 FY 2023 revenues compared to 2022 levels. Since the start of this year, Thermo Fisher has cut nearly 600 jobs in the US after the shutdown of three manufacturing sites in California. Despite this, a GlobalData job signal report stated they have been the top recruiter in the medical device industry over the past three months from May 2023. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Flagship Pioneering Investments
413 Investments
Flagship Pioneering has made 413 investments. Their latest investment was in Quotient Therapeutics as part of their Series A on November 11, 2023.
Flagship Pioneering Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/22/2023 | Series A | Quotient Therapeutics | $50M | Yes | 1 | |
9/28/2023 | Series B | Harbinger Health | $140M | No | Catalyst, M&G Investments, Partners Investment, Pictet Group, and Undisclosed Investors | 2 |
9/15/2023 | Series G | Indigo Ag | $250M | No | 3 | |
9/14/2023 | Series C | |||||
8/9/2023 | Series B |
Date | 11/22/2023 | 9/28/2023 | 9/15/2023 | 9/14/2023 | 8/9/2023 |
|---|---|---|---|---|---|
Round | Series A | Series B | Series G | Series C | Series B |
Company | Quotient Therapeutics | Harbinger Health | Indigo Ag | ||
Amount | $50M | $140M | $250M | ||
New? | Yes | No | No | ||
Co-Investors | Catalyst, M&G Investments, Partners Investment, Pictet Group, and Undisclosed Investors | ||||
Sources | 1 | 2 | 3 |
Flagship Pioneering Portfolio Exits
91 Portfolio Exits
Flagship Pioneering has 91 portfolio exits. Their latest portfolio exit was Senda Biosciences on October 19, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/19/2023 | Merger | 3 | |||
10/19/2023 | Merger | 1 | |||
5/25/2022 | Spinoff / Spinout | 1 | |||
Date | 10/19/2023 | 10/19/2023 | 5/25/2022 | ||
|---|---|---|---|---|---|
Exit | Merger | Merger | Spinoff / Spinout | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 3 | 1 | 1 |
Flagship Pioneering Fund History
9 Fund Histories
Flagship Pioneering has 9 funds, including Flagship Pioneering - Origination Fund VII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
6/14/2021 | Flagship Pioneering - Origination Fund VII | $3,400M | 3 | ||
3/20/2019 | Flagship Pioneering Special Opportunities Fund II | ||||
12/20/2017 | Flagship Pioneering Fund VI | ||||
12/15/2016 | Flagship Ventures Opportunities Fund I | ||||
3/26/2015 | Flagship Ventures Fund V |
Closing Date | 6/14/2021 | 3/20/2019 | 12/20/2017 | 12/15/2016 | 3/26/2015 |
|---|---|---|---|---|---|
Fund | Flagship Pioneering - Origination Fund VII | Flagship Pioneering Special Opportunities Fund II | Flagship Pioneering Fund VI | Flagship Ventures Opportunities Fund I | Flagship Ventures Fund V |
Fund Type | |||||
Status | |||||
Amount | $3,400M | ||||
Sources | 3 |
Flagship Pioneering Partners & Customers
10 Partners and customers
Flagship Pioneering has 10 strategic partners and customers. Flagship Pioneering recently partnered with Pfizer on July 7, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/18/2023 | Partner | United States | Flagship Pioneering and Pfizer Partner to… `` Flagship Pioneering and Pfizer enter into this strategic alliance driven by a shared sense of urgency to develop novel medicines that make a difference for patients , '' said Paul Biondi , President , Pioneering Medicines , and Executive Partner , Flagship Pioneering . | 1 | |
3/7/2023 | Partner | United States | `` Ampersand Biomedicines is using powerful computational tools , combined with our integrated screening capabilities , to engineer and optimize medicines across both physical and biological constraints , to produce therapies that act as intended , conditionally at the site of disease , '' said Avak Kahvejian Ph.D. , Co-Founder and CEO of Ampersand Biomedicines and Flagship Pioneering General Partner . | 1 | |
2/16/2023 | Licensor | United States | `` We 're entering this collaboration with both Charles River and Valo Health , Inc with a shared desire to increase efficiency in drug discovery , '' said Paul Biondi , President , Pioneering Medicines and Executive Partner , Flagship Pioneering . | 1 | |
5/18/2022 | Partner | ||||
5/18/2022 | Partner |
Date | 7/18/2023 | 3/7/2023 | 2/16/2023 | 5/18/2022 | 5/18/2022 |
|---|---|---|---|---|---|
Type | Partner | Partner | Licensor | Partner | Partner |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | Flagship Pioneering and Pfizer Partner to… `` Flagship Pioneering and Pfizer enter into this strategic alliance driven by a shared sense of urgency to develop novel medicines that make a difference for patients , '' said Paul Biondi , President , Pioneering Medicines , and Executive Partner , Flagship Pioneering . | `` Ampersand Biomedicines is using powerful computational tools , combined with our integrated screening capabilities , to engineer and optimize medicines across both physical and biological constraints , to produce therapies that act as intended , conditionally at the site of disease , '' said Avak Kahvejian Ph.D. , Co-Founder and CEO of Ampersand Biomedicines and Flagship Pioneering General Partner . | `` We 're entering this collaboration with both Charles River and Valo Health , Inc with a shared desire to increase efficiency in drug discovery , '' said Paul Biondi , President , Pioneering Medicines and Executive Partner , Flagship Pioneering . | ||
Sources | 1 | 1 | 1 |
Flagship Pioneering Service Providers
1 Service Provider
Flagship Pioneering has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | General Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
Flagship Pioneering Team
30 Team Members
Flagship Pioneering has 30 team members, including current Founder, Chief Executive Officer, Noubar Afeyan.
Name | Work History | Title | Status |
|---|---|---|---|
Noubar Afeyan | Sana Biotechnology, Ring Therapeutics, Cellarity, Laronde, Omega Therapeutics, Repertoire Immune Medicines, Cygnal Therapeutics, Kaleido Biosciences, Evelo Biosciences, CiBO Technologies, Codiak Biosciences, Rubius Therapeutics, Seres Therapeutics, Axcella Health, Joule Unlimited, LS9, Codon Devices, Helicos BioSciences, Adnexus Therapeutics, Epitome Biosystems, Ensemble Therapeutics, Affinnova, Selventa, Bg Medicine, MIT Sloan, Applera, Celera Genomics, ChemGenics Pharmaceuticals, and Perseptive Biosystems | Founder, Chief Executive Officer | Current |
Name | Noubar Afeyan | ||||
|---|---|---|---|---|---|
Work History | Sana Biotechnology, Ring Therapeutics, Cellarity, Laronde, Omega Therapeutics, Repertoire Immune Medicines, Cygnal Therapeutics, Kaleido Biosciences, Evelo Biosciences, CiBO Technologies, Codiak Biosciences, Rubius Therapeutics, Seres Therapeutics, Axcella Health, Joule Unlimited, LS9, Codon Devices, Helicos BioSciences, Adnexus Therapeutics, Epitome Biosystems, Ensemble Therapeutics, Affinnova, Selventa, Bg Medicine, MIT Sloan, Applera, Celera Genomics, ChemGenics Pharmaceuticals, and Perseptive Biosystems | ||||
Title | Founder, Chief Executive Officer | ||||
Status | Current |
Loading...